IVIG (intravenous immunoglobulin) works by flooding your bloodstream with concentrated antibodies collected from thousands of healthy donors, which then calm an overactive immune system through several overlapping mechanisms. Rather than targeting one specific pathway, IVIG acts like a multi-tool: it blocks the receptors immune cells use to attack your own tissues, dials down inflammation, neutralizes harmful autoantibodies, and boosts the population of immune cells responsible for keeping the peace. The exact balance of these effects depends on the dose and the condition being treated.
What IVIG Actually Is
IVIG is a purified solution of immunoglobulin G (IgG), the most common type of antibody in human blood. Each batch is manufactured from pooled plasma donated by thousands of healthy individuals, which means it contains a massive, diverse library of antibodies reflecting the collective immune experience of all those donors. This diversity is key to how it works. The product is administered directly into a vein over several hours, allowing the antibodies to circulate throughout the body almost immediately.
Blocking the Immune System’s “Attack” Receptors
One of the best-understood mechanisms involves receptor saturation. Your immune cells have surface receptors (called Fc receptors) that act like docking stations. When autoantibodies latch onto your own cells and flag them for destruction, these Fc receptors are what immune cells use to grab on and carry out the attack. High-dose IVIG floods these receptors with harmless IgG molecules, essentially occupying all the parking spots so the destructive autoantibodies can’t trigger an immune response. This is why IVIG can produce rapid improvement in conditions where the immune system is destroying platelets, nerve coatings, or other tissues.
Turning Down Inflammation
IVIG reduces levels of key inflammatory signaling molecules in the blood. In patients with Guillain-Barré syndrome, a condition where the immune system attacks peripheral nerves, IVIG treatment significantly lowered circulating levels of TNF-alpha and IL-1 beta, two of the body’s most potent inflammatory signals. By day five after treatment, unbound TNF-alpha was measurably lower in IVIG-treated patients compared to those who received plasma exchange or no treatment. Notably, IVIG didn’t raise levels of anti-inflammatory signals. It appears to work primarily by suppressing the inflammatory side of the equation rather than boosting the calming side.
IVIG also interferes with the complement system, a cascade of proteins that amplifies immune attacks. The infused antibodies bind to early complement components and help inactivate them, essentially diverting the complement cascade away from its target tissues and into the bloodstream where it dissipates harmlessly. This prevents the kind of collateral tissue damage that drives many autoimmune flare-ups.
Neutralizing Harmful Autoantibodies
Because IVIG contains such a vast library of antibodies, some of them happen to recognize and bind to the specific autoantibodies causing disease. These are called anti-idiotypic antibodies: antibodies that target other antibodies. When they lock onto pathogenic autoantibodies, they physically prevent those autoantibodies from binding to your own tissues. Think of it as putting a cap on a key so it no longer fits its lock. This mechanism has been documented in conditions like antiphospholipid syndrome, where harmful antibodies interfere with normal blood clotting and pregnancy.
Expanding the Immune System’s Peacekeepers
Your immune system has a built-in population of regulatory T cells whose job is to prevent other immune cells from going rogue. IVIG increases the number of these regulatory cells. It does this indirectly: the infused antibodies interact with a specific receptor on dendritic cells (the immune system’s scouts), which triggers those cells to produce a signaling molecule called prostaglandin E2. That molecule, in turn, stimulates regulatory T cells to multiply. Research published in Blood demonstrated this chain of events both in lab settings and in animal models of autoimmune disease, where blocking the prostaglandin pathway eliminated IVIG’s protective effect. This expansion of regulatory T cells helps restore immune tolerance, meaning the immune system becomes less likely to attack the body’s own tissues over time.
Replacement vs. Immunomodulatory Dosing
IVIG serves two fundamentally different purposes depending on the dose. At lower doses of 200 to 400 mg per kilogram of body weight given roughly every three weeks, it acts as replacement therapy for people whose immune systems don’t produce enough antibodies on their own. These patients are vulnerable to infections, and IVIG simply fills in the gap with borrowed immunity.
At high doses of 2 grams per kilogram per month, the goal shifts entirely. This is when the immunomodulatory mechanisms described above kick in. The sheer volume of antibodies is what enables receptor saturation, complement diversion, and regulatory T cell expansion. For a 70-kilogram adult, a high-dose course means infusing 140 grams of IgG, a massive quantity that temporarily reshapes how the immune system behaves.
How Quickly It Works
Response time varies by condition. In chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), a nerve disorder, about 47% of patients who ultimately responded showed measurable improvement by week three after their first infusion. The remaining responders needed a second infusion three weeks later before improvement became apparent, bringing the total to 53% improved by week six. Some conditions like immune-related low platelet counts can respond within days, while others require repeated cycles before the benefits accumulate.
The effects are temporary. Because IgG molecules are gradually broken down by the body, the benefits of each infusion fade over weeks. This is why most patients on IVIG for autoimmune conditions receive it on a recurring schedule, typically every three to four weeks.
Common Side Effects
Most side effects are mild and happen during or shortly after the infusion. In a study of 478 infusions, about 26% were associated with at least one adverse event. The most frequent were fever (13.6% of infusions), headache (6.7%), rapid heart rate (6.5%), and nausea or vomiting (5.9%). Rash occurred in about 3% of infusions. The majority of these reactions were mild and resolved without treatment.
Serious complications are uncommon but real. Blood clots occurred in 0.8% of infusions, red blood cell destruction (hemolysis) in 1.0%, and severe allergic reactions in 0.6%. Overall, about 16% of all adverse events were classified as severe or serious. Infusion rates are typically started slowly and increased gradually to minimize reactions, and many side effects can be managed by slowing the drip or pre-treating with medications like acetaminophen or antihistamines.